Improved spontaneous erectile function in men with mild-tomoderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year： a randomized trial

瞄准：为了测试假设，那 sildenafil (为一年夜里的 50 mg ) 能与 mild-to-moderate arteriogenic 在人改进自发的可勃起的功能(EF ) 可勃起的机能障碍(编辑) 对 erectogenic 处理应答。方法：在未来的开标签的试用，有编辑的 112 个人被使随机化到 sildenafil 夜里的 50 mg 或 sildenafil 需要 for12 月的 50 或 100 mg，由一个月和 6 月的非药物治疗的时期列在后面。非使随机化，有编辑的 non-medicatedmen 也被估计。可勃起的功能(IIEFEF ) 和山峰的国际索引的 EF 领域阴茎多孔的动脉的收缩速度(PSV ) 被用来测量功效。结果：在 sildenafil 处理和一个随后的非药物治疗的月以后， IIEF EF 在 48 中的 29 个是正常的(60.4% ， 95% 信心间隔[CI ] ：45.3-74.2%) 夜里的组对 4 of49 (8.2% ， 95% CI：2.3-19.6%) 同样需要的组。PSV 由 11.2 cm/s 改善了(95% CI：4.7-21.4；P= 0.012 ) 在夜里的组，但是仅仅由 3.4 cm/s (-5.1-14.7；P = 0.435 ) 在同样需要的 group.IIEF， EF 在 18 中的 1 个使正常化(5.6% ， 95% CI：0.1-27.3%) 非药物治疗的人和 PSV 稍微拒绝了。在处理，正常的仍然是的 IIEF EF 和 PSV 以后的六个月在大多数被稳定(28/29， 97%) 开始使正常化的夜里的组人。结论：为一年夜里的 Sildenafil 导致了在处理的结束以后坚持了很好的编辑回归，以便 spontaneousEF 在大多数人在 IIEF 上作为正常被描绘。从这开标签的、使随机化的试用的结果在双窗帘下面保证确认，控制安慰剂的条件。

Aim： To test the hypothesis that sildenafil （50 mg nightly for one year） can improve spontaneous erectile function （EF） in men with mild-to-moderate arteriogenic erectile dysfunction （ED） responsive to erectogenic treatment. Methods： In a prospective open-label trial, 112 men with ED were randomized to sildenafil 50 mg nightly or sildenafil 50 or 100 mg as needed for 12 months, followed by one-month and 6-month non-medicated periods. Non-randomized, non-medicated men with ED were also assessed. The EF domain of the International Index of Erectile Function （IIEF EF） and the peak systolic velocity （PSV） of penile cavernous arteries were used to measure the efficacy. Results： After sildenafil treatment and a subsequent non-medicated month, IIEF EF was normal in 29 of 48 （60.4%, 95% confidence interval [CI]： 45.3-74.2%） of the nightly group vs. 4 of 49 （8.2%, 95% CI： 2.3-19.6%） of the as-needed group. PSV improved by 11.2 cm/s （95% CI： 4.7-21.4; P = 0.012） in the nightly group but only by 3.4 cm/s （-5.1- 14.7; P = 0.435） in the as-needed group. IIEF EF normalized in 1 of 18 （5.6%, 95% CI： 0.1-27.3%） non-medicated men and the PSV declined slightly. Six months after treatment, the IIEF EF remained normal and PSV was stabilized in most （28/29, 97%） nightly group men who had initially normalized. Conclusion： Sildenafil nightly for one year resulted in ED regression that persisted well beyond the end of treatment, so that spontaneous EF was characterized as normal on the IIEF in most men. The results from this open-label, randomized trial warrant verification under double-blind, placebo-controlled conditions.